First Results From Editas CRISPR Eye Therapy Underwhelm Investors

Safety Is Reassuring But Efficacy Unclear

 
• By Andrew McConaghie
  
Editas
Editas is one of a handful of biotechs developing in vivo CRISPR therapies, alongside the likes of Intellia and CRISPR Therapeutics • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip